Golimumab and Actemra Will Be Two of the Most Successful Emerging Novel Agents in the Rheumatoid Arthritis Drug Treatment Market
Posted on: Monday, 16 June 2008, 09:01 CDT
WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Roche/Chugai's Actemra will be two of the most successful emerging novel agents in the rheumatoid arthritis drug market over the next decade in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
The new Pharmacor report entitled Rheumatoid Arthritis finds that the novel TNF-alpha inhibitor golimumab will be one of the most commercially successful emerging agents for rheumatoid arthritis, due to its more- convenient intravenous and subcutaneous dosing formulations, compared with the formulations of other current and emerging TNF-alpha inhibitors. Additionally, due to its novel mechanism of action, the interleukin-6 inhibitor Actemra will successfully compete with Bristol-Myers Squibb's Orencia and Biogen Idec/Genentech/Chugai/Zenyaku Kogyo's Rituxan / Roche's MabThera in the treatment of rheumatoid arthritis patients who respond inadequately to TNF-alpha inhibitors.
The report also finds that Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira -- both currently marketed TNF-alpha inhibitors -- will continue to dominate the rheumatoid arthritis market. Driven by their continued uptake as first-line treatments among biological agents, sales of Enbrel and Humira for rheumatoid arthritis will be close to $4 billion for each drug by 2017.
"Most of the sales growth over the next 10 years will occur through 2012, driven by continued uptake of currently marketed drugs and the launch of several novel biological agents," said Dancella Fernandes, Ph.D., analyst at Decision Resources. "From 2012 to 2017, annual market growth will slow due to fewer new product launches, restrictions imposed by third-party payers that will prevent expansion of biological therapy into earlier lines of treatment, biogeneric erosion and smaller increases in the rates of diagnosis and drug treatment."
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- India's Rheumatoid Arthritis Drug Market Will More Than Double by 2013
- Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
- For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia
- Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013
- China's Rheumatoid Arthritis Drug Market Will More than Double by 2013
- For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
- ACTEMRA(R) (Tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
- Greater Uptake of Abbott/Eisai's Humira in the Treatment of Rheumatoid Arthritis and Crohn's Disease Will Drive Growth in the TNF-Alpha Inhibitor Market Through 2011
- Roche and Toyama Chemical Enter Licensing Agreement to Develop Potential Breakthrough Drug to Treat Rheumatoid Arthritis
 |
 |
User Comments (0)
RSS Feeds